Floatz logo

TEMUTERKIB

KRAS Mutation-Related Tumors

The Netherlands Cancer InstituteSmall moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

20 Active assets in the KRAS Mutation-Related Tumors cohort.

Asset / SponsorPhaseRating
Binimetinib
Abramson Cancer Center at Penn Medicine
Phase 2B
Hydroxychloroquine
Abramson Cancer Center at Penn Medicine
Phase 2B
Irinotecan
Institut de Recherches Internationales Servier
Phase 1/2CCC
FLUOROURACILUM
Institut de Recherches Internationales Servier
Phase 1/2CCC
Calcium folinate pentahydrate
Institut de Recherches Internationales Servier
Phase 1/2CCC

View all 25 →

Same molecule, other indications

TEMUTERKIB is also rated in:

cancerDormant
CCC
Indicative ·
55 / 100
View asset →
pancreatic neoplasmDormant
CCC
Indicative ·
50 / 100
View asset →
colorectal carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →